Chemomab Therapeutics Ltd.

CMMBNASDAQHealthcare● Active

$1.81

+$0.04(+2.25%)

Market Cap$11139531

P/E Ratio—

52W High$5.48

52W Low$1.35

Avg Volume46K

Open$1.84

Beta0.61

Net Income Financials Revenue

Chemomab Therapeutics Ltd. (CMMB) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

CMMB · net income · updated Jun 8, 2026

Core profitability metrics

CMMB · net income · margin · TTM · CAGR

Net income was −$9.0M for FY2025 (fiscal year ending 2025-12-31), up 35.5% year-over-year. Net profit margin was —. Based on available data, Chemomab Therapeutics Ltd. has been profitable since at least 2012.

FY2025 Net Income−$9.0M▲ +35.5% YoY

Trailing 12M (TTM)−$7.5Mtrailing 4 quarters sum

Net Profit Margin——

YoY Change+35.5%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2012

▸ FMP /income-statement · Annual · CMMB net income history · CMMB profit margin

Annual net income data

CMMB · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$9.0M▲ +35.5%—$0

FY2024Loss−$13.9M▲ +42.4%—$0

FY2023Loss−$24.2M▲ +12.4%—$0

FY2022Loss−$27.6M▼ 121.6%—$0

FY2021Loss−$12.5M▼ 109.7%—$0

Net income vs peers (Healthcare)

CMMB vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Chemomab Therapeutics Ltd.YOU

CMMB

−$9.0M+35.5%—

Loss

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Chemomab Therapeutics Ltd. (CMMB) reported net income of −$9.0M for FY2025 (fiscal year ending 2025-12-31), up 35.5% year-over-year. The net profit margin was — — meaning the company kept $— of every dollar of revenue as profit.

Based on available data, Chemomab Therapeutics Ltd. has been profitable since at least 2012. Net income reached a peak of $24.2M in FY2012. Data available for 15 fiscal years.

Chemomab Therapeutics Ltd.'s net profit margin was — for FY2025, based on the latest annual results.

Investors sometimes search for "Chemomab Therapeutics Ltd. net worth" — the company's market capitalization is a separate figure from CMMB net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

CMMB net income · 4 questions

Chemomab Therapeutics Ltd. is not currently profitable on an annual basis. The company reported a net loss of $9.0M for FY2025.

is CMMB profitabledoes CMMB make a profitCMMB profitabilityCMMB profitable company

▸ Source: FMP /income-statement · GAAP · Chemomab Therapeutics Ltd. · Chemomab Therapeutics Ltd. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026